MCG
SONN

McCollum Christoferson Group’s Sonnet BioTherapeutics SONN Stock Holding History

McCollum Christoferson Group’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-230
Closed -$19.8K – 73
2023
Q2 		$19.8K Buy
+230
New +$16.2K 0.01% 70

Other funds holding SONN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

McCollum Christoferson Group's SONN Position: Q3 2023 in Review

McCollum Christoferson Group sold out of Sonnet BioTherapeutics (SONN) in Q3 2023, closing a stake of 230 shares — an estimated $19.8K sold.

McCollum Christoferson Group first reported a position in SONN in Q2 2023 and held it in 1 quarter. The position peaked at $19.8K in Q2 2023. 9 funds tracked by Wall St. Rank hold SONN as of Q3 2023.

  • McCollum Christoferson Group reported no remaining Sonnet BioTherapeutics position as of Q3 2023 after selling out during the quarter.
  • McCollum Christoferson Group sold 230 Sonnet BioTherapeutics shares in Q3 2023, an estimated $19.8K.
  • McCollum Christoferson Group first reported a position in Sonnet BioTherapeutics in Q2 2023 and held it in 1 quarter.
  • McCollum Christoferson Group's Sonnet BioTherapeutics position peaked at $19.8K in Q2 2023.
  • 9 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2023.

Based on McCollum Christoferson Group's 13F filing for Q3 2023, filed 8 Nov 2023.